Destiny Pharma (LON:DEST) Shares Up 0.8%

Destiny Pharma plc (LON:DEST) rose 0.8% on Monday . The company traded as high as GBX 18.42 ($0.23) and last traded at GBX 18.39 ($0.23). Approximately 232,775 shares were traded during mid-day trading, a decline of 56% from the average daily volume of 523,981 shares. The stock had previously closed at GBX 18.25 ($0.23).

Analysts Set New Price Targets

Separately, Shore Capital reaffirmed a “house stock” rating on shares of Destiny Pharma in a research note on Wednesday, January 31st.

Destiny Pharma Stock Up 0.8 %

The stock has a market cap of £17.53 million, a price-to-earnings ratio of -306.50 and a beta of 0.24. The company’s 50-day simple moving average is GBX 25.96 and its 200-day simple moving average is GBX 50.51.

Destiny Pharma Company Profile

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.